drugset / Trial / NCT04322617
Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study aims to explore the efficacy of Anlotinib with or without Immune Checkpoint Inhibitor in Standard Chemo-immunotherapy Failed Advanced NSCLC.
Timeline
- Start
- 2020-03-24
- Primary completion
- 2028-03-24
- Completion
- 2029-03-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 8 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | Sintilimab | Monoclonal antibody | — | — |